Stella Diagnostics (OTCMKTS:SLDX) Receives Breakthrough Award as Best Clinical Proteomics Solution
Shares of Stella Diagnostics (OTCMKTS:SLDX) closed higher in the previous session. The stock has lost 5% in the past week.
Market Stats
On Wednesday, SLDX stock gained 5.26% to $1 with more than 3.8K shares, compared to its average volume of 590 shares. The stock moved within a range of $0.8500 – 0.9500 after opening trading at $0.95.
Stella Diagnostics Named ‘Best Clinical Proteomics Solution’ of 2021 by Biotech Breakthrough Awards
Molecular diagnostics-based organization, Stella Diagnostics (OTCMKTS:SLDX), has announced that its STLA101 mass spec proteomic assay (BEsmart) was selected as the winner of the “Best Clinical Proteomics Solution of the Year” award for 2021 in the inaugural awards program conducted by BioTech Breakthrough.
Stella Diagnostics is working towards providing comprehensive information to gastroenterologists, oncologists and pathologists regarding the molecular expression trends indicative of disease stability, progression and/or carcinogenesis. The goal is to take it beyond routine gross and microscopic screening of esophageal diseases.
Esophageal adenocarcinoma, linked to Barrett’s esophagus, has one of the highest mortality rates in oncology, as more than 80% of patients diagnosed with esophageal adenocarcinoma have already progressed to advanced-stage cancer at the time of diagnosis. The mass spectroscopy-based proteomic assay, STLA101 gives physicians a clear insight into the molecular properties of their patients’ tissue. It helps to determine if the disease is stable, progressing, or venturing towards cancerous.
As of now, the company is currently undergoing optimization on its BEsmart proteomic panel (STLA101) in partnership with mProbe, Inc., and has entered into several collaborative research agreements with leading institutions around the U.S., including the Mayo Clinic and Kansas University Medical Center, to assess assay performance of the BEsmart Test.
Key Quote
Dr. Joe Abdo, CEO of Stella Diagnostics, said, “We are very grateful to have Stella Diagnostics’ novel STLA101 assay recognized by BioTech Breakthrough for its massive potential clinical utility. Rather than rest on our accolades, this award will serve as motivation for our team to remain steadfast in attaining clinical adoption of STLA101 as a first-line diagnostic tool for patients receiving endoscopies for Barrett’s esophagus. This award supports our mission that providing more robust molecular data of diseased esophageal tissue compared to the current standard of care is a clinical need in gastroenterology.”
